What does a diagnosis of prostatic adenocarcinoma with Gleason score 6 (3 + 3) Grade Group 1 and identified perineural invasion indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What This Diagnosis Means

Your pathology report shows the lowest grade of prostate cancer (Grade Group 1), which is considered very low-risk disease with excellent prognosis, though the presence of perineural invasion is a common microscopic finding that does not change the favorable outlook of this specific cancer grade.

Understanding Your Cancer Grade

Your diagnosis contains three key components:

Gleason Score 6 (3+3) / Grade Group 1

  • This represents the lowest grade of prostate cancer recognized in modern pathology 1, 2
  • Grade Group 1 consists of "only individual discrete well-formed glands" - the most organized and least aggressive pattern 2
  • This is classified as very low risk or low risk disease depending on other factors like PSA density, number of positive cores, and percentage of core involvement 1

Why It's Still Called "Cancer"

Despite ongoing debate, Grade Group 1 remains designated as cancer because 3, 4:

  • It has the microscopic features of malignancy (invasive growth, lacks normal basal cells)
  • It shares molecular and genetic characteristics with higher-grade prostate cancers 5
  • It can demonstrate extraprostatic extension, though rarely
  • Calling it "non-cancer" would create confusion in reporting and follow-up

However, the critical point is that Grade Group 1 has extremely low risk of metastasis and cancer-related death 1, 3

About Perineural Invasion (PNI)

What It Means

Perineural invasion means cancer cells are found around nerve fibers in the prostate tissue.

Clinical Significance in Grade Group 1

In your specific situation with Grade Group 1 disease, perineural invasion does NOT worsen your prognosis:

  • PNI is present in approximately 90% of prostate cancers overall and is a common microscopic finding 6
  • Multiple studies show that PNI parameters (nerve size, proximity to margins, density) do not independently predict biochemical recurrence when controlling for grade and stage 6
  • In favorable-risk disease like yours, PNI on biopsy is not associated with grade upgrading at surgery and should not be a concern for more aggressive disease 7
  • The prognostic factors that actually matter are: Gleason score/Grade Group, PSA level, and clinical stage - not PNI 6

Important Caveat

While some older studies suggested PNI predicted extraprostatic extension 8, more recent and rigorous analyses show this loses significance on multivariate analysis when grade and PSA are considered 6. In Grade Group 1 specifically, PNI should not drive treatment decisions.

What This Means for Your Care

Based on current guidelines 1:

You are a candidate for active surveillance if you meet very low risk criteria:

  • ≤2 positive biopsy cores
  • ≤50% cancer in any single core
  • PSA density <0.15 ng/ml/cc
  • Clinical stage T1c-T2a

Active surveillance has shown:

  • Very favorable outcomes in Grade Group 1 patients
  • Low probability of adverse pathology if surgery is eventually needed
  • Low rate of metastatic disease with careful monitoring 1

Key Takeaway

Your cancer grade (Grade Group 1) is the dominant prognostic factor - the perineural invasion is a microscopic observation that does not change your excellent prognosis or treatment approach 6, 7. Treatment decisions should be based on your overall risk stratification (incorporating PSA, clinical stage, and biopsy characteristics), not on the presence of PNI 1, 2.

Related Questions

What is the best treatment approach for a 65-year-old male with End-Stage Renal Disease (ESRD) on dialysis and a Gleason score 8 prostate cancer with no evidence of metastasis?
What are the treatment options for a 77-year-old man with Gleason 6 (3+3) prostate adenocarcinoma involving 4 of 14 cores and focal high‑grade prostatic intra‑epithelial neoplasia (PIN) present in 3 of 12 cores?
A patient’s prostate biopsy shows Gleason Grade Group IV (Gleason score 8). What is the clinical stage of his prostate cancer and what are the appropriate treatment options?
For a patient with a prostate biopsy showing a positive core but a Gleason grade other than 6, what is the recommended management?
What is the recommended management for a patient with Gleason 3 + 4 (score 7) prostate cancer and a PSA of 4 ng/mL?
What are the maximum daily doses of haloperidol (Haldol) and bupropion (Wellbutrin) that can be safely co‑administered in an adult without cardiac disease or seizure disorder?
What is the proper technique and dosage for injecting a small dose of bupivacaine into a tender trigger point in the trapezius muscle?
In a patient with inferior‑wall myocardial ischemia, how should isosorbide dinitrate (ISDN) be administered, including indications, dosing, and monitoring?
What is the difference between the Miami criteria and the modified Miami criteria for intraoperative parathyroid hormone (PTH) monitoring?
How many drops per milliliter are in bromfenac 0.9% ophthalmic solution (1.7 mL)?
Is there an association between abdominal bloating and methylphenidate use?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.